Sohel_Parvez_Haque/iStock via Getty Images
- The U.S. FDA has awarded Fast Track Designation to PTC Therapeutics' (NASDAQ:PTCT) candidate for Huntington's Disease, PTC518.
- The oral drug reduces the production of the mutated Huntingtin protein.
- In June, PTC released promising interim data from a phase 2 study of the asset.